GlassScriptPhysician profile
Madison Walsh
NPI 1841881430
$2,836.86
in general payments reported to CMS, 2019-2025
14 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $400 · 2023: $631 · 2024: $1,618 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,929 · Travel and Lodging: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,928.78 |
| Travel and Lodging | $507.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,396.98 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $263.48 | 2022-2023 | Camzyos |
| Csl Behring | $158.09 | 2023-2025 | Kcentra, Haegarda |
| Pfizer INC. | $155.97 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.56 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $150.08 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.54 | 2022-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $99.73 | 2022-2023 | |
| Daiichi Sankyo INC. | $79.91 | 2022-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $64.03 | 2022-2025 | Farxiga, Wainua |
| Atricure, INC. | $62.15 | 2024 | |
| Merck Sharp & Dohme LLC | $46.84 | 2023 | Verquvo |
| Abbvie INC. | $43.87 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $37.63 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.